5-MeO-DiBF (5-methoxy-N,N-diisobutyl-2-aminobenzofuran), also described as a methoxybenzofuran analog of 5-MeO-DiPT, is a synthetic psychedelic compound belonging to the substituted benzofuran class rather than the classical tryptamine family. The compound's benzofuran core — a bicyclic ring system consisting of a benzene ring fused to a furan ring — structurally distinguishes it from tryptamines (which have an indole core), though the two classes share functional groups and appear to share serotonergic mechanisms.
5-MeO-DiBF represents an interesting structural bridge between the classical tryptamine psychedelics and the more unusual benzofuran class. It is hypothesized to act primarily through 5-HT1A and 5-HT2 receptor family agonism, consistent with other methoxy-substituted serotonergic compounds. The presence of the 5-methoxy group — shared with the highly potent 5-MeO-DMT — is a critical structural feature that strongly influences serotonin receptor binding and subjective character.
Community documentation of 5-MeO-DiBF is very sparse. It is one of the less commonly encountered research chemicals even within the benzofuran class. Its effects are characterized primarily through a small number of community experience reports and by structural extrapolation from related compounds. The diisobutyl N-substitution creates a molecule of substantial steric bulk, which may affect receptor binding and duration relative to the simpler 5-MeO analogs.
Safety at a Glance
High Risk- Extreme Caution Due to Limited Documentation
- Estimated threshold: low (potency likely amplified by 5-methoxy group)
- Toxicity: Limited Data 5-MeO-DiBF has extremely limited toxicological data available. The benzofuran scaffold is distinct from ...
- Overdose risk: Fatal overdose from 5-MeO-DiBF alone, at doses within the typical recreational range, is extremel...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 4 hrs – 6 hrsHow It Feels
The onset of 5-MeO-DiBF is gradual and subtle, establishing itself over thirty to fifty minutes as a quiet shift in baseline consciousness. A mild warmth builds in the body, accompanied by a slight heaviness in the limbs and a faint tingling in the extremities. The mental effects are similarly understated: a gentle alteration of mood, a slight loosening of habitual thought patterns, and a growing sense of present-moment awareness that is pleasant but not dramatic.
As the experience develops over the next hour, the perceptual changes remain modest. Visual effects are minimal — perhaps a slight brightening of colors, a barely perceptible softening of edges, or an increased appreciation for visual detail that might be attributable as much to heightened attention as to pharmacological alteration. The primary effects are felt in the body and in the quality of consciousness rather than in dramatic perceptual distortions. There is a gentle mood elevation, a sense of calm wellbeing that settles over the experience like a light blanket. The body may feel slightly warmer and more relaxed than usual. Sounds are perceived with perhaps marginally greater clarity but without significant distortion.
The peak, arriving around sixty to ninety minutes and lasting one to two hours, is gentle by any psychedelic standard. The headspace is clear and functional — thought processes are subtly altered but not impaired. There may be a contemplative quality to thinking, a tendency toward reflection and introspection that is inviting rather than compulsive. Physical comfort is generally good, with mild relaxation and occasional waves of pleasant warmth. There is little to no visual geometry, no ego dissolution, and no challenging psychological material; the experience operates at a level of subtlety that might not be recognized as psychedelic by someone expecting more dramatic effects.
The comedown is smooth and gradual, the mild alterations fading over one to two hours. The total duration is three to five hours. There is very little residual effect, and the overall experience is best characterized as a gentle, exploratory nudge at the edges of psychedelic space. Given the limited number of experience reports available, individual responses may vary considerably, and what is described here represents a general impression drawn from sparse data rather than a well-established consensus.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(8)
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(7)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(11)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Rejuvenation— A renewed sense of physical vitality, mental freshness, and emotional restoration that can emerge du...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(4)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
Transpersonal(1)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
Pharmacology
Benzofuran Scaffold vs. Tryptamine Scaffold
5-MeO-DiBF is built on a benzofuran core rather than the indole core of tryptamines. The benzofuran is a bioisostere of indole in some contexts — both are bicyclic heteroaromatic systems capable of engaging serotonin receptors — and several benzofuran compounds have been shown to be active at 5-HT2A and 5-HT1A receptors. The structural similarity between 5-MeO-DiBF and 5-MeO-DiPT (the tryptamine analog with identical N-substituents) has been used to rationalize predicting similar pharmacological activity.
Serotonin Receptor Activity
5-MeO-DiBF is hypothesized to act as a partial agonist at 5-HT2A receptors and/or 5-HT1A receptors, consistent with other methoxyphenylethylamine and methoxy indole compounds. The 5-methoxy group is known to dramatically increase serotonin receptor binding potency in the indole series (as evidenced by 5-MeO-DMT being substantially more potent than DMT), and a similar enhancement is expected in the benzofuran series.
The diisobutyl N-substitution creates a sterically bulky molecule that may reduce intrinsic efficacy at 5-HT2A receptors while maintaining binding affinity — a pattern that sometimes results in partial agonist behavior with a ceiling on psychedelic intensity.
Lack of Formal Data
No published receptor binding data or human pharmacokinetic studies exist for 5-MeO-DiBF. All pharmacological characterization is based on structural extrapolation and the small number of community experience reports.
Estimated Pharmacokinetics
Based on structural analogy: oral activity expected (diisobutyl groups substantially reduce MAO-A affinity). Onset: 30–60 minutes orally. Duration: 3–5 hours. No formal data.
Detection Methods
Urine Detection
5-MeO-DiBF is not targeted by standard immunoassay-based urine drug screens. 5-MeO-substituted tryptamines are metabolized primarily through hepatic pathways involving CYP2D6 and monoamine oxidase enzymes, producing demethylated and hydroxylated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect these metabolites in urine for approximately 24 to 48 hours after ingestion, though the detection window varies with dose and individual metabolic rate. The short duration of action of most 5-MeO tryptamines correlates with a relatively brief detection window.
Blood and Serum Detection
Blood detection windows for 5-MeO-DiBF are short, typically 2 to 8 hours after administration depending on the route. Smoked or insufflated routes produce rapid peak concentrations followed by swift clearance, while oral administration (particularly with MAO inhibition) extends both the effect and detection windows. LC-MS/MS is required for reliable blood quantification at the low nanogram-per-milliliter concentrations typical of 5-MeO tryptamines.
Standard Drug Panel Inclusion
5-MeO-DiBF is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. 5-MeO tryptamines do not cross-react with any standard immunoassay panel targets. There is no reliable cross-reactivity with amphetamine, opiate, or any other standard immunoassay. Detection requires a specific request for tryptamine testing at a laboratory with novel psychoactive substance capabilities.
Confirmatory Methods
Definitive identification of 5-MeO-DiBF requires LC-MS/MS or GC-MS analysis with compound-specific reference standards. Some forensic toxicology laboratories include 5-MeO-DMT in their expanded tryptamine panels, but coverage of other 5-MeO variants is less common. Bufotenin (5-HO-DMT), a metabolite of 5-MeO-DMT, may also be targeted. Quantitative analysis requires validated methods, as the structural similarity among 5-MeO tryptamines can complicate chromatographic separation without optimized conditions.
Reagent Testing (Harm Reduction)
The Ehrlich reagent produces a purple to violet reaction with 5-MeO-DiBF, confirming the presence of an indole ring characteristic of all tryptamines. This is the primary field identification tool and should always be the first test performed. The Hofmann reagent provides a confirmatory blue reaction. The Marquis reagent typically shows no reaction or a faint yellow to brown discoloration with 5-MeO tryptamines. Because 5-MeO tryptamines can be significantly more potent by weight than 4-substituted analogs, reagent testing alone is not sufficient for safe use. Quantitative analysis and accurate dosing are critically important for this subclass.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins and Structural Context
5-MeO-DiBF belongs to the class of substituted benzofuran psychedelics that emerged as research chemicals in the early-to-mid 2000s. The benzofuran class was explored partly as a structural alternative to scheduled tryptamines, with researchers and chemists investigating which features of the tryptamine pharmacophore were essential for psychedelic activity and whether they could be replicated in the benzofuran scaffold.
The compound is structurally analogous to 5-MeO-DiPT (foxy methoxy) — a tryptamine with a documented psychedelic profile that achieved some popularity in the research chemical market in the early 2000s. 5-MeO-DiBF substitutes the benzofuran core for the indole core while maintaining the 5-methoxy group and diisobutyl N-substitution.
Research Chemical Status
5-MeO-DiBF is among the more obscure entries in the research chemical catalog, with limited community documentation and very limited formal scientific attention. It occupies a position of structural interest — a methoxy benzofuran analog of a known psychedelic tryptamine — but has not generated the community use or scientific investigation of more accessible compounds.
Contemporary Status
5-MeO-DiBF remains a compound of primarily theoretical structural interest and occasional research chemical availability. No clinical research program has examined it. Community experience reports are sparse. It is best approached with the caution appropriate to a structurally novel, little-characterized compound with a potency-enhancing 5-methoxy substituent.
Harm Reduction
Extreme Caution Due to Limited Documentation
5-MeO-DiBF is one of the least documented compounds in this batch. The combination of a novel scaffold, 5-methoxy substitution (associated with high potency in related compounds), and essentially absent human safety data demands exceptional caution.
Dosing
- Estimated threshold: low (potency likely amplified by 5-methoxy group)
- First-time doses: start very low (5 mg or less orally)
- Do not assume equivalence to any other compound
- Milligram-accurate scale required
Structural Novelty Caution
The benzofuran scaffold is not a tryptamine scaffold. Do not extrapolate safety data from tryptamines without reservation. The metabolic profile, acute toxicity, and full pharmacological profile are not established.
5-Methoxy Caution
Compounds with the 5-methoxy indole/benzofuran motif can be significantly more potent than their unmethoxylated analogs. Apply the conservative dosing principle strongly.
Standard Protocol
Test with available reagents (Ehrlich reagent is primarily for indole tryptamines — positive result confirms indole content, but benzofurans may give an attenuated or negative result). Full psychedelic preparation. Sober experienced companion strongly recommended. Benzodiazepines available.
Toxicity & Safety
Limited Data
5-MeO-DiBF has extremely limited toxicological data available. The benzofuran scaffold is distinct from the tryptamine scaffold, and the toxicological assumptions applicable to tryptamines should not be uncritically extended to this compound.
Cardiovascular Concerns
The 5-methoxy group is associated with potent serotonergic activity, and 5-MeO compounds as a class can produce more pronounced cardiovascular effects (tachycardia, blood pressure elevation) than 4-substituted analogs. The benzofuran version shares this structural feature.
Psychological Risks
Given the 5-methoxy substitution — which in 5-MeO-DMT is associated with intense, occasionally overwhelming ego dissolution — caution is warranted even at moderate doses. The limited community experience with 5-MeO-DiBF means that dose-response relationships are poorly characterized.
Unknown Risks
The benzofuran scaffold introduces structural novelty relative to the well-characterized tryptamine class. The chronic toxicity and metabolic profile of benzofuran compounds is less well established than for tryptamines. Caution is accordingly amplified for this compound.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 5-MeO-DiBF alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
5-MeO-DiBF is currently thought to be a legal grey area substace in many parts of the world. However, although it is easily accessible through the use of online research chemical vendors, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.
Germany: 5-MeO-DiBF is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: 5-MeO-DiBF is a controlled substance specifically named under Verzeichnis E.
United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
Responsible use
Psychedelic
Tryptamine
5-MeO-DiBF (Wikipedia)
5-MeO-DiBF (Isomer Design)
Community
5-MeO-DiBF (UK Chemical Research)
5-MeO-DIBF (Benzofuran analogue of 5-MeO-DIPT) (BlueLight)
Experience Reports (2)
Tips (5)
Do not combine 5-MeO-DiBF with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
Start with a low dose of 5-MeO-DiBF if it is your first time. You can always take more next time but you cannot take less once ingested. The difference between a comfortable and an overwhelming experience can be surprisingly small.
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 5-MeO-DiBF. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 5-MeO-DiBF and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Integration is just as important as the experience itself. After using 5-MeO-DiBF, take time to journal, reflect, or discuss the experience. Insights from psychedelic states can be powerful but need conscious effort to apply to daily life.
See Also
References (5)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- PubChem: 5-MeO-DiBF
PubChem compound page for 5-MeO-DiBF (CID: 125276632)
pubchem - 5-MeO-DiBF - TripSit Factsheet
TripSit factsheet for 5-MeO-DiBF
tripsit - 5-MeO-DiBF - Wikipedia
Wikipedia article on 5-MeO-DiBF
wikipedia